Effects of a Shuangling Fuzheng anticancer preparation on the proliferation of SGC-7901 cells and immune function in a cyclophosphamide-treated murine model.
OBJECTIVE
To study the inhibitory effects of a Shuangling Fuzheng anticancer preparation (SFAP) on the human gastric cancer cell line SGC-7901 in vitro as well as its immune-modulated effects in a cyclophosphamide-treated murine model.


METHODS
MTT experiments and immunocytochemistry ABC experiments were performed for detecting the proliferation of SGC-7901 cells in vitro and protein expression of c-myc. The staphylococcal protein A (SPA) rosette test was utilized for measuring the ratio of T-lymphocyte subsets from peripheral blood in a cyclophosphamide-treated murine model. Enzyme-linked immunosorbant assay (ELISA) was performed for measuring the levels of serum sIL-2R in treated mice, while immunoturbidimetry was used for measuring the levels of immunoglobulins (Ig).


RESULTS
SFAP (40-640 mg/L, 48 h) inhibited the proliferation of SGC-7901 cells, and a positive correlation was noted between inhibitory effects and dosage. At a dosage of 160-320 mg/L in cultured cells, the expression of c-myc was decreased. SFAP (50-200 mg/kg) increased the percentage of CD3+ and CD4+ T-lymphocytes, the ratio of CD4/CD8, and the contents of Ig such as IgM, IgG or IgA, but decreased the levels of serum sIL-2R in peripheral blood from cyclophosphamide-treated mice.


CONCLUSIONS
SFAP can inhibit the proliferation of SGC-7901 cells via the c-myc gene. In addition, SFAP can modulat the cellular and humoral immunity in cyclophosphamide-induced immunosuppressed mice.
Chen
Hua-Sheng
HS
Yangzhou University Medical College, Yangzhou 225001, Jiangsu Province, China. yzcwy050130@sina.com
Chen
Jue
J
Cui
De-Li
DL
Zheng
Yuan-Yuan
YY
Xu
Ai-Hua
AH
Chen
Gang
G
Jia
Ling-Chang
LC
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D003520:Cyclophosphamide / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007136:Immunoglobulins / Q000097:blood; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D051379:Mice; D008813:Mice, Inbred ICR; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000097:blood; D013274:Stomach Neoplasms / Q000378:metabolism / Q000473:pathology*; D016176:T-Lymphocyte Subsets / Q000378:metabolism / Q000473:pathology
D000972:Antineoplastic Agents, Phytogenic; D004365:Drugs, Chinese Herbal; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; C489427:MYC protein, human; D016271:Proto-Oncogene Proteins c-myc; D015375:Receptors, Interleukin-2; C531092:Shuangling Fuzheng anticancer preparation; D003520:Cyclophosphamide